Page last updated: 2024-12-11

motretinide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

motretinide: exerts a therapeutic influence on chemically induced papillomas & carcinomas of the skin in mice; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6314185
CHEMBL ID519260
CHEBI ID135490
SCHEMBL ID3546
MeSH IDM0056661

Synonyms (49)

Synonym
AC-18534
ro-11-1430
tasmaderm
nsc-351523
56281-36-8
nsc351523
2,6,8-nonatetraenamide, n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-e)-
motretinide
2,6,8-nonatetraenamide, n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all e)-
(all-e)-n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenamide
2,4,6,8-nonatetraenamide, n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2e,4e,6e,8e)-
motretinidum [inn-latin]
2,4,6,8-nonatetraenamide, 3,7-dimethyl-n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-e)-
motretinid
ccris 5815
motretinide [usan:inn]
brn 2169960
ro 11-1430
2,4,6,8-nonatetraenamide, n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-e)-
motretinida [inn-spanish]
einecs 260-094-6
all-trans-n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenamide
motretinide (usan/inn)
D05082
tasmaderm (tn)
CHEBI:135490
CHEMBL519260
(2e,4e,6e,8e)-n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenamide
54757-59-4
trans-n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenamide
2,4,6,8-nonatetraenamide, n-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-
trimethylmethoxyphenyl-n-ethyl retinamide
tmmp ethyl ester
tmmp-era
AKOS015964309
unii-w786807kl1
motretinida
w786807kl1 ,
nsc 351523
motretinidum
motretinide [inn]
motretinide [mi]
motretinide [usan]
motretinide [mart.]
motretinide [who-dd]
SCHEMBL3546
DB13368
Q904009
DTXSID30878633

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" These differences between the results obtained in vivo and in vitro could be resolved by pharmacokinetic investigations using HPLC methods."( Transplacental pharmacokinetics of teratogenic doses of etretinate and other aromatic retinoids in mice.
Kochhar, DM; Kraft, JC; Löfberg, B; Nau, H; Reiners, J, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
retinoidOxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1130659Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 20 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID334311Induction of morphological transformation of rat ASK cells into astrocytes after 1 hr by light microscopy
AID1130654Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas compound treated ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID1130653Toxicity in mouse assessed as hypervitaminosis dose compound treated ip daily monday through friday in first week and monday through thursday in second week measured after 1 day of last injection1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID1130661Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 5 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID1130658Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 40 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
AID1130660Antipapilloma activity against Hart Swiss albino mouse assessed as decrease in chemically-induced papillomas at 10 mg/kg, ip for 5 days/week for 2 weeks1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Fluorinated retinoic acids and their analogues. 1. Synthesis and Biological activity of (4-methoxy-2,3,6-trimethylphenyl)nonatetraenoic acid analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.38 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (33.33%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (61.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]